MS patients rate their injection experience: kesimpta vs ocrevus
NCT ID NCT06668324
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study surveyed 134 adults with multiple sclerosis who were starting treatment with either Kesimpta or the newer subcutaneous (under-the-skin) version of Ocrevus. The goal was to compare how patients felt about their first injection, including any pain, redness, swelling, or itching at the injection site. Results will help understand which treatment might offer a better starting experience for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ofatumumab (Kesimpta) and ocrelizumab subcutaneous (Ocrevus SC)
What this could lead to
If successful, this could help doctors and patients choose between these two MS treatments based on real-world injection experiences.
What could go wrong
This is a small, completed survey study, not a treatment trial. It only measures patient-reported reactions, not long-term effectiveness or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative site
East Hanover, New Jersey, 07936, United States